Argenx Se · EURONEXT:ARGX
Argenx — Investor Presentation (September 2022)
21 slides from Argenx's investor presentation, September 2022
Slide 1: Together We Discover: Corporate Presentation September 2022
Together We Discover Reaching Patients Through Immunology Innovation Corporate Presentation September 2022
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Our Plan to Build a Leading Immunology Company
Our Plan to Build a Leading Immunology Company Driving revolution in autoimmunity with precision medicines Committed to Reaching patients globally our Patients and their Communities Vibrant neuromuscular, hematology, skin and kidney franchises argenx 2025 Enviable Immunology Efgartigimod in 15 indic
Slide 4: Strong Execution in First Half 2022
Strong Execution in First Half 2022 1 Global VYVGART® Sales $75M in net Q2 product sales Strong launch performance in U.S. and Japan 2 Global Launch Approved in EU and launched in Germany; BLA accepted in China Positive ADVANCE-IV data in ITP 3 Positive Phase 3 Data Positive ADAPT-SC data in gMG - B
Slide 5: Multiple Data Readouts in 2023
Multiple Data Readouts in 2023 First Quarter 2023 Second Half 2023 5
Slide 6: Executing on VYVGART Launch Priorities
Executing on VYVGART Launch Priorities Meeting our stakeholders where they are Empower Patients Best-in-Class Rapid HCP Enable to Demand Better Patient Adoption of Appropriate Support VYVGART Access $75M 10 mg/kg 2Q 2022 Net Product Sales Intravenous infusion 6
Slide 7: Significant Growth in Patients on Therapy
Significant Growth in Patients on Therapy A P P R O X I M AT E LY 1400 “ I no longer have to use two hands to brush my teeth - one to hold the toothbrush and the other to hold my arm up. I was able to keep my eyes open enough to read a book for the first PAT I E N T S O N VYVGART time in 5 years. I’
Slide 8: Shifting Prescribers from Initial Use to Broad Adoption
Shifting Prescribers from Initial Use to Broad Adoption Awareness Interest 78% of prescribing physicians have written 1 or 2 scripts; Shift to broad adoption key HCPs Evaluation indicator of growth trajectory Initial Use Adoption 8
Slide 9: Key Pillars of VYVGART Value-Based Agreement
Key Pillars of VYVGART Value-Based Agreement 4Q 2021 25% Of Covered Lives Affordability Predictability Simplicity 1Q 2022 62% Of Covered Lives 2Q 2022 Most VYVGART-specific policies are favorable and aligned to label, with prior authorization median of 6 months 85% Of Covered Lives J-Code in effect
Slide 10: Global gMG Launch Progressing
Global gMG Launch Progressing VYVGART Approved December 17, 2021 United States Japan China (Zai Lab) Gulf Region (GenPharm) Launched May 9, 2022 Filed and accepted in 2Q 2022 Israel (Medison) Europe Filed in 2Q 2022 Launched in Germany Canada September 1, 2022 Central and Eastern Europe Global (Medi
Slide 11: Innovative Trial Accelerated Path Forward
ADAPT-SC Bridging Study Innovative Trial Accelerated Path Forward Leveraged PK/PD • Leveraged correlation between pharmacodynamic and clinical effect as observed in ADAPT from ADAPT • Met primary endpoint, demonstrating noninferior total IgG Met Primary reduction at day 29 with subcutaneously admini
Slide 12: Differentiated Treatment Options for gMG Patients
Differentiated Treatment Options for gMG Patients SC efgartigimod ADAPT-NXT single injection Continuous Dosing Future Delivery Vehicles and Formulations (e.g., pre-filled syringe, Elektrofi, autoinjector) Eri, living with gMG 12 12
Slide 13: Results Support Path Forward
ADVANCE-IV Phase 3 Results Support Path Forward • Statistically significant and clinically meaningful Primary endpoint met improvement in platelet counts over placebo • Fast and robust platelet count improvement over placebo Meaningful patient benefit observed • Ability for every other week dosing c
Slide 14: ITP is the Second Indication with a Positive Phase 3 Read-out for VYVGART
ITP is the Second Indication with a Positive Phase 3 Read-out for VYVGART LEVERAGE FORMULATIONS ACROSS MULTIPLE INDICATIONS, THERAPEUTIC gMG ITP Pemphigus CIDP Myositis BP Membranous Lupus COVID-19- Sjogren’s FRANCHISES, AND Nephropathy Nephritis mediated Syndrome MOLECULES POTS 4/4 (gMG, ITP, PV, C
Slide 15: New Efgartigimod Translational Data
New Efgartigimod Translational Data Demonstrating our scientific leadership in FcRn biology, providing new insights into pathophysiology of autoimmune skin blistering diseases and potential role of FcRn blockade Maho-Vaillant M et al. FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cell
Slide 16: ARGX-117: Sweeping Antibody Designed to Target Unique Intervention in Complement
ARGX-117 Blocks C2 ARGX-117: Sweeping Antibody Classical Lectin Designed to Target Unique IgG C1 qrs IgM Mannose sugar MAS Ps MBL Intervention in Complement C4 C2 C3 convertase Targeting C2: C3a C3 C3b • Leaves alternative pathway intact against infection C5 convertase • Blocks all complement effect
Slide 17: ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease
ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease Oury, J., Zhang, W., Leloup, N. et al. Mechanism of disease and therapeutic ARGX-119 ( ) induces AChR clustering, NMJ maturation and stabilization rescue of Dok7 congenital myasthenia. Nature 595, 404–408 (2021). https://doi.org/10
Slide 18: Global Multifranchise Autoimmune Portfolio
Sjogren’s Congenital MG Global Multifranchise ALS SMA Autoimmune Portfolio MuSK MG Long COVID-19 POTS Efgartigimod MMN Kidney DGF INDICATIONS BP MOLECULES Skin LN ARGX-117 ROW IIM China THERAPEUTIC Israel FRANCHISES Heme MN Europe CIDP Canada PV Neuro ARGX-119 GLOBAL ITP Japan MARKETS gMG US gMG: ge
Slide 19: Advancing Cusatuzumab in AML with OncoVerity
Advancing Cusatuzumab in AML with OncoVerity Leveraging Co-creation to maximize expertise of value creation potential our partners spinoff to emerge 4th from discovery engine Combining novel translational biology insights …With encouraging data on the role of CD70/CD27 pathway in AML… from our first
Slide 20: Progressing Toward 'argenx 2025'
LEADING WITH THE SCIENCE, FOCUSED ON THE PATIENT Progressing Toward ‘argenx 2025’ Reach patients • Drive continued momentum in U.S. and Japan globally • Initial EU launch in Germany Expand gMG • Bring additional optionality to gMG community with SC launch in 2023 offering • Phase 3 data readouts of
Slide 21: Where critical patient need meets breakthrough science
Where critical patient need meets breakthrough science That is where we redefine immunology 21